Patents Assigned to Medimmune Vaccines, Inc.
-
Patent number: 7204990Abstract: A method is provided for attenuating a cytomegalovirus comprising functionally disrupting an open reading frame of a Toledo genome region or its homolog and making chimeric CMV virus genomes.Type: GrantFiled: November 28, 2000Date of Patent: April 17, 2007Assignee: MedImmune Vaccines, Inc.Inventors: George Kemble, Gregory M. Duke, Richard Spaete
-
Publication number: 20070031941Abstract: The present invention provides novel canine pol I regulatory nucleic acid sequences useful for the expression of nucleic acid sequences in canine cells such as MDCK cells. The invention further provides expression vectors and cells comprising such nucleic acids as well as methods of using such nucleic acids to make influenza viruses, including infectious influenza viruses.Type: ApplicationFiled: August 9, 2006Publication date: February 8, 2007Applicant: MEDIMMUNE VACCINES, INC.Inventors: Gregory Duke, George Kemble, James Young, Zhaoti Wang
-
Publication number: 20060286591Abstract: The present invention provides novel canine pol I regulatory nucleic acid sequences useful for the expression of nucleic acid sequences in canine cells such as MDCK cells. The invention further provides expression vectors and cells comprising such nucleic acids as well as methods of using such nucleic acids to make influenza viruses, including infectious influenza viruses.Type: ApplicationFiled: June 20, 2006Publication date: December 21, 2006Applicant: MEDIMMUNE VACCINES, INC.Inventors: Gregory Duke, George Kemble, James Young, Zhaoti Wang
-
Patent number: 7135180Abstract: This invention provides methods and compositions to preserve bioactive materials in a dried foam matrix. Methods provide non-boiling foam generation and penetration of preservative agents at temperatures near the phase transition temperature of the membranes.Type: GrantFiled: April 10, 2003Date of Patent: November 14, 2006Assignee: MedImmune Vaccines, Inc.Inventor: Vu Truong-Le
-
Publication number: 20060252132Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: ApplicationFiled: March 6, 2006Publication date: November 9, 2006Applicant: MEDIMMUNE VACCINES, INC.Inventors: Chin-Fen Yang, George Kemble, Chongguang Liu
-
Publication number: 20060188977Abstract: The present invention provides novel MDCK-derived adherent non-tumorigenic cell lines that can be grown in the presence or absence of serum. The cell lines of the present invention are useful for the production of vaccine material (e.g., viruses). More specifically, the cell lines of the present invention are useful for the production of influenza viruses in general and ca/ts influenza viruses in particular. The invention further provides methods and media formulations for the adaptation and cultivation of MDCK cells such that they remain non-tumorigenic. Additionally, the present invention provides methods for the production of vaccine material (e.g., influenza virus) in the novel cell lines of the invention.Type: ApplicationFiled: December 16, 2005Publication date: August 24, 2006Applicant: MEDIMMUNE VACCINES, INC.Inventors: Richard Schwartz, John Berry, Ajit Subramanian, Xiao Shi
-
Publication number: 20060153872Abstract: Methods and compositions for the optimization and production of influenza viruses, e.g., ca influenza B strains, in eggs and host cells suitable as influenza vaccines are provided.Type: ApplicationFiled: December 7, 2005Publication date: July 13, 2006Applicant: MEDIMMUNE VACCINES, INC.Inventors: Qi Dang, Richard Schwartz
-
Publication number: 20060110406Abstract: Methods and compositions for the optimization and production of refrigerator-temperature stable virus, e.g., influenza, compositions are provided. Formulations and immunogenic compositions comprising refrigerator-temperature stable virus compositions are provided.Type: ApplicationFiled: October 4, 2005Publication date: May 25, 2006Applicant: MEDIMMUNE VACCINES, INC.Inventors: George Kemble, George Trager, Richard Schwartz
-
Publication number: 20060002862Abstract: This invention provides compositions and methods providing, e.g., stable powder particles containing bioactive materials. The methods include, e.g., high pressure spraying of the bioactive materials in solution or suspension, with viscosity enhancing agents, organic solvents, and/or surfactants. Formulations are provided for spraying therapeutic bioactive materials into powder particles containing amino acids and sugars. Compositions of the invention provide, e.g., high initial purity, high stability in storage, and reconstitution at high concentrations.Type: ApplicationFiled: June 13, 2005Publication date: January 5, 2006Applicant: MedImmune Vaccines, Inc.Inventors: Vu Truong-Le, Tom Scherer
-
Patent number: 6974686Abstract: Recombinant PB2 tryptophan variant influenza viruses, RNA, cDNA and vectors are provided. Also provided are immunogenic compositions containing the variant viruses, methods of producing such viruses and methods for the prophylactic treatment of influenza in humans.Type: GrantFiled: December 20, 2002Date of Patent: December 13, 2005Assignee: MedImmune Vaccines, Inc.Inventor: Neil T. Parkin
-
Publication number: 20050176130Abstract: The present invention provides recombinant respiratory syncytial viruses that have an attenuated phenotype and that comprise one or more mutations in the viral P, M2-1 and/or M2-2 proteins, as well as live attenuated vaccines comprising such viruses and nucleic acids encoding such viruses. Recombinant RSV P, M2-1 and M2-2 proteins are described. Methods of producing attenuated recombinant RSV, and methods of quantitating neutralizing antibodies that utilize recombinant viruses of family Paramyxoviridae, are also provided.Type: ApplicationFiled: September 26, 2003Publication date: August 11, 2005Applicant: MedImmune Vaccines, Inc.Inventors: Hong Jin, Bin Lu, Xing Cheng, Helen Zhou
-
Patent number: 6887699Abstract: Recombinant negative-strand viral RNA templates are described which may be used with purified RNA-directed RNA polymerase complex to express heterologous gene products in appropriate host cells and/or to rescue the heterologous gene in virus particles. The RNA templates are prepared by transcription of appropriate DNA sequences with a DNA-directed RNA polymerase. The resulting RNA templates are of the negative-polarity and contain appropriate terminal sequences which enable the viral RNA-synthesizing apparatus to recognize the template. Bicistronic mRNAs can be constructed to permit internal initiation of translation of viral sequences and allow for the expression of foreign protein coding sequences from the regular terminal initiation site, or vice versa.Type: GrantFiled: September 14, 1999Date of Patent: May 3, 2005Assignee: MedImmune Vaccines, Inc.Inventors: Peter Palese, Adolfo Garcia-Sastre
-
Publication number: 20050042229Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: ApplicationFiled: June 16, 2004Publication date: February 24, 2005Applicant: MedImmune Vaccines, Inc.Inventors: Chin-Fen Yang, George Kemble, Chongguang Liu
-
Patent number: 6843996Abstract: Recombinant PB2 variant influenza viruses, RNA, cDNA and vectors are provided. Also provided are immunogenic compositions containing the variant viruses, methods of producing such viruses and methods for the prophylactic treatment of influenza in humans.Type: GrantFiled: December 1, 1999Date of Patent: January 18, 2005Assignee: Medimmune Vaccines, Inc.Inventors: Neil T. Parkin, Kathleen L. Coelingh
-
Patent number: 6830748Abstract: The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene.Type: GrantFiled: August 3, 1999Date of Patent: December 14, 2004Assignee: MedImmune Vaccines, Inc.Inventors: Hong Jin, Roderick Tang, Shengqiang Li, Martin Bryant
-
Publication number: 20040224309Abstract: The complete polynucleotide sequence of the human respiratory syncytial virus subgroup B strain 9320 genome is provided. Proteins encoded by this polynucleotide sequence are also provided. Isolated or recombinant RSV (e.g., attenuated recombinant RSV), nucleic acids, and polypeptides, e.g., comprising mutations in the attachment protein G, are also provided, as are immunogenic compositions comprising such isolated or recombinant RSV, nucleic acids, and polypeptides. Related methods are also described.Type: ApplicationFiled: March 26, 2004Publication date: November 11, 2004Applicant: MedImmune Vaccines, Inc.Inventors: Xing Cheng, Hyun Jung Park, Hong Jin
-
Patent number: 6811784Abstract: The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.Type: GrantFiled: September 20, 2002Date of Patent: November 2, 2004Assignee: MedImmune Vaccines, Inc.Inventors: Aurelia Haller, Kathleen L. Coelingh
-
Publication number: 20040208895Abstract: The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.Type: ApplicationFiled: April 14, 2004Publication date: October 21, 2004Applicant: MedImmune Vaccines, Inc.Inventors: Aurelia Haller, Kathleen L. Coelingh
-
Patent number: 6764685Abstract: The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.Type: GrantFiled: March 21, 2000Date of Patent: July 20, 2004Assignee: MedImmune Vaccines, Inc.Inventors: Auriela Haller, Kathleen L. Coelingh
-
Patent number: 6713296Abstract: The invention provides for a novel VZV gene, mutant VZV and immunogenic compositions based on such novel genes and mutant VZV. Also provided are proteins, diagnostic assays and methods of producing reconstructed VZV.Type: GrantFiled: July 10, 2000Date of Patent: March 30, 2004Assignee: MedImmune Vaccines, Inc.Inventor: George William Kemble